Exchange: NYSE·Updated 07:59 PM EDT

TEVA News

News
all
press releases
Teva's Shares Now Trade Directly on the NYSE Here's What Else Changed
Teva Pharmaceutical Industries had a busy week that included a major debt refinancing, a NYSE trading shift and analyst activity.read more...
Benzinga
More News
Temporal Raises $550 Million in Series E Round: NYSE Content Update
Temporal Raises $550 Million in Series E Round: NYSE Content Update Temporal Raises $550 Million in Series E Round: NYSE Content UpdatePR NewswireNEW YORK, Sept. 14, 2026 NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Sept. 14, 2026 /PRNewswire/ -- The New York...
PR Newswire
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound?
BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
Zacks
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Zacks
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
Zacks
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.
Stocktwits
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid
TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.
Zacks
BioXcel Therapeutics Agrees To Teva Asset Sale
(RTTNews) - BioXcel Therapeutics Inc. (BTAI) on Friday entered into an agreement to sell substantially all of its assets to Teva Pharmaceuticals International GmbH (TEVA.TA) and filed for voluntary Chapter 11 bankruptcy...
Nasdaq News: Markets
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Zacks

Advertisement|Remove ads.